Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma

BACKGROUND: Adjuvant chemotherapy is the standard treatment after curative-intent surgery for pancreatic ductal adenocarcinoma (PDAC). The phase-3 ESPAC-4 trial demonstrated significantly improved overall survival (OS) with Gemcitabine plus capecitabine (GemCap) over Gemcitabine (Gem) in Europe. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Sora, Yoo, Changhoon, Lee, So Heun, Oh, Dongwook, Song, Tae Jun, Lee, Sang Soo, Jeong, Jae Ho, Park, Do Hyun, Seo, Dong Wan, Park, Jin-hong, Hwang, Dae Wook, Song, Ki Byung, Lee, Jae Hoon, Lee, Woohyung, Kwak, Bong Jun, Hong, Sarang, Chang, Heung-Moon, Ryoo, Baek-Yeol, Kim, Kyu-pyo, Kim, Song Cheol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092583/
https://www.ncbi.nlm.nih.gov/pubmed/35571606
http://dx.doi.org/10.1177/17588359221097190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9092583/
https://www.ncbi.nlm.nih.gov/pubmed/35571606
http://dx.doi.org/10.1177/17588359221097190

Ejemplares similares